ACTRN12621001309875
Completed
未知
A study to assess the effectiveness of a primary care vs central hub invitation to lung cancer screening for Maori participants aged 55-74 in Auckland and Waitemata District Health Boards
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- ung cancer screening
- Sponsor
- Waitemata District Health Board
- Enrollment
- 504
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants will be recorded or self\-identified as Maori in their primary care enrolment register,
- •Aged between 55 to 74,
- •Enrolled in participating general practices in Auckland or Waitemata District Health Boards
- •Are able to provide informed consent and able to agree to participate.
Exclusion Criteria
- •Never smokers,
- •Those with clinical symptoms suspicious for lung cancer,
- •Those with a previous diagnosis of lung cancer,
- •People who have received chemotherapy or cytotoxic drugs within the last six months,
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Preliminary study on evaluating the effectiveness of outpatient Morita therapy for agoraphobiaagoraphobiaJPRN-UMIN000042870Department of Neuropsychiatry, Keio University School of Medicine10
Active, not recruiting
Phase 1
Efficacy and safety of niraparib in combination with cabozantinib in patients with advanced urothelial cancer.EUCTR2017-004367-12-ESFundación CRIS de investigación para vencer el cáncer71
Active, not recruiting
Phase 1
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years oldMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10029261Term: Neuroblastoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-005617-14-DKovartis Pharma AG230
Active, not recruiting
Phase 1
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)EUCTR2021-005617-14-CZovartis Pharma AG230
Active, not recruiting
Phase 1
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years oldTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-005617-14-DEovartis Pharma AG230